AMG319

From WikiMD's Wellness Encyclopedia

AMG319 is a drug developed by Amgen which acts as an inhibitor of the phosphoinositide 3-kinase enzyme subtype PI3Kδ. It was originally developed as an anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-cancer effects, and it has been put into clinical trials to assess its safety and tolerability in this application.[1][2]

Mechanism(s) of action[edit | edit source]

It is a potential immunotherapy because blocking PI3Kδ (PI3K p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells.[3] p110δ inactivation in regulatory T  cells unleashes CD8+ cytotoxic T  cells.[4]

Clinical trials[edit | edit source]

Its first clinical trial was a phase I/II study in adults with relapsed or refractory lymphoid malignancies.[5] This was due to run from 2011 to 2013.

In 2015/16 it started a phase II clinical trial as a neoadjuvant therapy for human papillomavirus (HPV) negative head and neck squamous-cell carcinoma (HNSCC) (prior to resection surgery).[3]

See also[edit | edit source]

References[edit | edit source]

  1. ↑
  2. ↑ Lanasa MC, Glenn MJ, Mato AR, Allgood SD, Wong S, Amore B, Means GD, Stevens E, Yan C, Friberg G, Goy A. First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies. 55th ASH Annual Meeting and Exposition, December 2013
  3. ↑ 3.0 3.1 AMG 319 in Human PapillomaVirus (HPV) Negative HNSCC
  4. ↑
  5. ↑ A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 319 in Adult Subjects With Relapsed or Refractory Lymphoid Malignancies


AMG319 Resources
Retrieved from "https://wikimd.com/w/index.php?title=AMG319&oldid=2161530"

Contributors: Spt